Skip to Main Content
Skip Nav Destination

There have been no fundamental advances in the treatment of schizophrenia for decades, largely due to a poor understanding of the pathophysiology of the disorder. Since schizophrenia has a substantial genetic component, with estimated heritability of ∼65–80%, genomic studies provide a rational route to obtain novel mechanistic insights and facilitate the discovery of new drug targets and thence treatments. This chapter focuses on how recent genomic discoveries in schizophrenia, fuelled by technological advancements in high-throughput genomics and computational biology, are helping to identify novel therapeutic targets, as well as allowing for more effective and safe use of existing medications.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal